African American mothers continue to have the lowest breastfeeding rates, even as the breastfeeding rates have risen in the US over the past 25 years.
In a study of more than 10,600 adult patients hospitalized with COVID-19, women had significantly lower odds than men of in-hospital mortality. They also had fewer admissions to the intensive care unit and less need for mechanical ventilation.
An alternate-day intermittent fasting schedule offered less fat-reducing benefits than a matched "traditional" diet that restricts daily energy intake, according to a new, 3-week randomized trial involving 36 participants.
Underrepresented populations in clinical research, and more in the latest issue.
Research published in the journal ACS Materials and Interfaces has provided new understanding of how false-negative results in Lateral Flow Tests occur and provides opportunity for simple improvements to be made.
Evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic was unprecedented in terms of urgency and scope. Responsibility for the safety, integrity and scientific validity of U.S. trials fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board, who in turn report to an oversight group. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.
A "3D Culture System" developed by University of Southampton has closely replicated how cells infected with TB change in the human lung. Analytical evidence of these changes identified 7 key gene changes that cause damage in the lungs, from hundreds of thousands. A second trial showed that a common antibiotic, doxycycline, could help reverse these changes and speed up recovery.
Through a pre-clinical study conducted in his former role at Moffitt Cancer Center and published in Clinical Cancer Research, Said Sebti, Ph.D., associate director for basic research at VCU Massey Cancer Center, identified a novel drug that effectively thwarts pancreatic tumors that are addicted to the cancer-causing mutant KRAS gene.
New treatment combination for hepatitis C virus (HCV) is an additional affordable option for millions still waiting for access to lifesaving treatments in middle-income countries. Combination is safe and effective, including for hard-to-treat cases and people with HCV and HIV. New drug ravidasvir is the first HCV drug to be developed through South-South collaboration and with support from non-profit organizations.
Oregon Health & Science University researchers have developed a new approach to gene therapy that uses the common pain reliever acetaminophen to force a variety of genetic diseases into remission.